Imatinib is a specific inhibitor of the BCR::ABL1 fusion protein and is an example of successful targeted therapy, still being the treatment of choice for most of de novo CML patients with low-risk disease. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.